BIOCARDIA INC

BCDANASDAQ

🏆 #3642 by market capEarnings Aug 12US Equity

$0.93▼ $0.03 (−3.61%)

🌙 After hours$0.93▼ 0.23%Regular close · extended-hours price shown

1h—

24h▼ 3.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$14M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

100.0%

High

💵FCF Margin

76.6%

Strong

⚖️P/S Ratio

33.0x

Expensive

Otter Score

Weak

No chart data available for BCDA.

Trading Snapshot

Day Range: $0.92 – $0.95
52-Week Range: $0.75 – $2.29
Volume: $2.59B
Avg Volume: $3.22B
Shares Outstanding: 14.9M
Next Earnings: Oct 21, 2026

Fundamentals Snapshot

Annual Revenue: $436,233
Last Q Revenue: $121,096
P/E Ratio: —
P/S Ratio: 33.0x
EPS (TTM): $-0.80
Dividend Yield: —

Why Investors Own BCDA

✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
✓Healthy economics — 76% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$436,233▼ −6.8% YoY

Gross Margin (TTM)

75.7%▲ +0.2% YoY

Operating Income (TTM)

$80,703▼ −6.8% YoY

Free Cash Flow (TTM)

$39,697▼ −6.8% YoY

About BIOCARDIA INC

BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.

🦦